



J. Vet. Sci. (2006), 7(4), 361–368
Effects of DDA, CpG-ODN, and plasmid-encoded chicken IFN-γ on 
protective immunity by a DNA vaccine against IBDV in chickens
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This study examined the adjuvant effects of dimethyl
dioctadecyl ammonium bromide (DDA), CpG oligodeoxy-
nucleotides (CpG-ODN), and chicken interferon- γ (ChIFN-γ)
on a DNA vaccine (pcDNA-VP243) against the infectious
bursal disease virus (IBDV). A plasmid encoding chicken
IFN-ã was constructed. Twice at 2-week intervals, two-
week-old chickens were injected intramuscularly and
intraperitoneally with either a DNA vaccine alone or a
DNA vaccine together with the respective adjuvants. On
week 2 after the second immunization, the chickens were
orally challenged with the highly virulent IBDV. The
groups that received the DNA vaccines plus either DDA or
CpG-ODN showed significantly lower survival rates than
the group that received the DNA vaccine alone. However,
the survival rates for the DNA vaccine alone and for the
DNA vaccine plus ChIFN-γ were similar. The chickens
had no detectable antibodies to the IBDV before the
challenge but all the surviving chickens in all groups
except for the normal control group showed the induction
of antibodies to the IBDV at day 10 after the challenge. As
judged by the lymphocyte proliferation assays using the a
WST-8 solution performed on the peripheral blood and
splenic lymphocytes, the stimulation indices (SI) of the
peripheral blood lymphocytes in all groups except for the
normal control group were similar immediately before the
challenge. At 10 days post-challenge, the SI for DNA
vaccine plus either CpG-ODN or ChIFN-γ was similar to
that of the DNA vaccine control group. For splenic
lymphocytes, the SI in the DNA vaccine plus CpG-ODN
and DNA vaccine plus ChIFN-γ groups were higher than
for the DNA vaccine control. These results suggest that
DDA actually compromises the protection against the
IBDV by DNA vaccine, and CpG-ODN and IFN-γ had no
significant effect.
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Introduction
New types of vaccines such as recombinant vaccines or
DNA vaccines in some diseases have largely supplanted the
traditional methods of vaccination, which utilize live or dead
whole microorganisms [9,30,38]. Although DNA vaccines
have many advantages over conventional vaccines, some
new generations of vaccines have the drawback that DNA
vaccines require repeated doses or mixing with strong adjuvants
to achieve an effective immune response [13,25,28]. Therefore,
recent vaccine studies have focused on discovering efficient
adjuvants.
Adjuvants with DNA vaccines are essential for achieving
sufficient levels of protection and long-term immunity.
Suitable adjuvants must be able to increase the immune
response without having any undesirable side effects.
Conventional oil-based adjuvants deteriorate the meat
quality at the injection sites. Hence, either naturally occurring
adjuvants such as cytokines or other types of compatible
adjuvants are needed [25].
Interferon-γ (IFN-γ) is a cytokine produced by stimulated
T cells and has important effects in immunomodulation [8].
Its properties as an adjuvant have been examined in a large
number of animal studies [1,5,11,25,40,46]. Dimethyl
dioctadecyl ammonium bromide (DDA) has been recognized
as an adjuvant for enhancing both humoral and cell-
mediated immune responses [18]. Unmethylated cytosine-
phosphate-guanosine (CpG) dinucleotides are sequences
that are found in the bacterial DNA that have adjuvant
properties in the mammalian immune system by activating
antigen-presenting cells (APCs) [20,24]. In addition, CpG-
containing oligodeoxynucleotides (CpG-ODNs) induce the
secretion of various cytokines, including interleukin-6 (IL-
6) and type II interferon (IFN-γ) [47,48].
Infectious bursal disease (IBD) or Gumboro disease,
which is caused by the infectious bursal disease virus
(IBDV), is an acute and highly contagious disease in
chickens 3 weeks of age and older. The disease has an
important economic impact on the poultry industry
worldwide because it is associated with a high mortality and
immunosuppression in recovered chickens, which leads
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both to a variety of secondary infections and a a decreased
response to vaccinations [26]. After the emergence of highly
virulent IBDV strains that cause high mortality in Europe
and the antigenic variants of IBDV in USA, these IBDVs
have spread rapidly despite conventional vaccination programs
to protect chickens against IBDV infections [1,4,34].
This study examined the adjuvant effects of a plasmid
encoding chicken IFN-γ, of DDA, and of CpG-ODN on a
plasmid DNA vaccine (pcDNA-VP243) against the highly
virulent IBDV SH/92 strain, which was developed in our
laboratory [17], in chickens. The results suggest that CpG-
ODN and IFN-γ failed to enhance the DNA vaccine
efficacy, and that DDA actually had an adverse effect on the
level of protection against the IBDV.
Materials and Methods
Chickens
The fertilized eggs of specific pathogen free (SPF) White
Leghorn were obtained (Sunrise Farm, USA) and hatched.
The hatched chicks were placed into plastic isolators
operated under a positive air pressure and provided with
food and water ad libitum during the experimental period.
Construction and preparation of plasmids
The DNA vaccine, pcDNA-VP243, encoding the VP2,
VP4, and VP3 proteins of the highly virulent IBDV SH/92
strain, is described elsewhere [17]. The plasmid DNA was
purified from the transformed Escherichia coli using the
Endofree Plasmid Giga Kit (Qiagen, USA).
For cloning of the IFN-γ gene, the spleens were obtained
aseptically from 8-week old SPF chickens. After the spleens
had been passed through a plastic cell strainer (Becton
Dickinson Labware, USA), the spleen lymphocytes were
separated by Histopaque-1077 (Sigma, USA). The prepared
splenocytes were rinsed three times in Hanks balanced salt
solution (HBSS) and incubated at 1 × 10
7cells/mL for 6 h in
RPMI-1640 medium containing 10% fetal bovine serum
(FBS) supplemented with 12.5 µg/mL Concanavalin A (ConA,
Sigma, USA), at 40
oC and 5% CO2. The total RNA was
isolated and purified from harvested splenocytes using the
TRIzol reagent (Invitrogen, USA) according to the
manufacturer’s recommendation, and the cDNA was
synthesized using random primers (Invitrogen, USA). The
PCR fragments were synthesized from cDNA using the
primers, CIG-F (5' GCCGCCGCCATGACTTGCCAGAC
TTACAAC 3') and CIG-R (5' TTAGCAATTGCATCTCCT
CTG 3'), which were synthesized according to the published
sequence of chicken IFN-γ [6]. PCR was performed with 35
cycles of denaturation at 95
oC for 1 min, annealing at 55
oC
for 1 min, and extension at 72
oC for 2 min. The final
extension step was performed at 72
oC for 10 min. The PCR
products were analyzed on a 1.0 % agarose gel.
The PCR products were purified utilizing a GENECLEAN
Turbo kit (Q-biogene, USA) according to the manufacturer’s
instructions. The purified PCR products were cloned into
the pcDNA 3.1/V5/His-TOPO vector (Invitrogen, USA)
and transformed into competent Escherichia coli (TOP 10)
cells (Invitrogen, USA). The plasmid DNA was isolated
using the E.N.Z.A plasmid miniprep kit I (Omega Bio-tech,
USA). The nucleotide sequence and the orientation of the
plasmid construct were confirmed by DNA sequencing. The
verified plasmid construct was named pcDNA-ChIFN-ã,
and large quantities of the plasmid were prepared using a
Endofree Plasmid Giga Kit (Qiagen, USA).
Synthetic CpG-ODN and preparation of DDA solution
The CpG-ODN (2007) sequence [32] is TCGTCGTTGT
CGTTTTGTCGTT (underlining indicates CpG dinucleotides),
which was produced with a phosphorothioate backbone
(Bioneer, Korea). Synthetic CpG-ODN (10 µg/bird) along
with the DNA vaccine was injected. A DDA (Sigma, USA)
solution (2 mg/bird) was prepared as described previously
[16] and also injected along with the DNA vaccine.
In vitro transcription and translation
The in vitro expression of pcDNA-ChIFN-γ was performed
using the TNT Quick Coupled Transcription/Translation
System (Promega, USA) and visualized using the Transcend
Colorimetric Translation Detection System (Promega, USA)
according to the manufacturer's recommendations. The
samples were electrophoresed on a 12% discontinuous SDS-
PAGE gel and transferred onto nitrocellulose membranes for
visualization. The membranes were washed with Tris-
buffered saline (TBS) and incubated in a blocking buffer
(TBS containing 0.5% Tween 20). For visualization,
streptavidin alkaline phosphatase was added to the membranes,
which were rocked gently for 60 min and visualized by
adding Western Blue Stabilized Substrate (Promega, USA).
Immunization protocols
Two-week-old SPF chickens were randomly divided into
6 experimental groups (9 birds/group), which included the
normal control (without vaccination and challenge), challenge
control (without vaccine but with challenge), DNA vaccine
alone (with pcDNA-VP243 DNA vaccine and challenge),
DNA vaccine plus DDA (with pcDNA-VP243 DNA
vaccine plus DDA and challenge), DNA vaccine plus CpG-
ODN (with pcDNA-VP243 DNA vaccine plus CpG-ODN
and challenge), DNA vaccine plus ChINF-γ (with pcDNA-
VP243 DNA vaccine plus ChINF-γ plasmid and challenge).
Twice at a 2-week interval, 2-week-old chickens were
injected intramuscularly (100 µg) and intraperitoneally (100
µg) with the DNA vaccines. For the DNA vaccine plus
ChINF-γ group, 125 µg of the pcDNA-ChIFN-γ plasmid
was injected intramuscularly into separate sites.
Two weeks later, all the groups except for the normal
control group were re-injected with the same dose and byEffects of adjuvants on IBDV DNA vaccines 363
the same route as used for the primary immunization. Two
weeks after the second immunization, all the groups except
for the normal control were challenged orally with a 1 × 10
4.8
50% egg lethal dose (ELD50) of the highly virulent IBDV
SH/92 strain [21]. The chickens were then monitored daily
for any clinical signs over a 10 day period. At 10 days post-
challenge, all the remaining chickens in each group were
euthanized, and the spleens and the bursa of Fabricius were
collected aseptically. The bursa/body weight (B/B) ratios
were calculated by (bursa weight)/(body weight) ×1,000.
Peripheral blood and splenic lymphocyte proliferation
assay
The lymphocyte proliferation assay was performed as
described previously [17]. Briefly, the whole blood and
spleens were collected aseptically from the chickens before
the challenge as well as at 10 days after the challenge, and
the cell suspensions were obtained. The lymphocytes were
separated using Histopaque-1077 (Sigma, USA), washed
three times, and then resuspended in RPMI-1640 medium
supplemented with 10% FBS. The cells (PBL at 1.25 × 10
6
cells/well and spleen at 2.5 × 10
6 cells/well) were placed in
96-well flat-bottomed tissue culture plates. ConA (12.5 µg/
mL) was added to each well except for the negative control
well. The plates were incubated for 48 h at 40
oC in a 5%
CO2 atmosphere. The lymphocyte proliferation activity was
measured using a WST-8 working solution [29]. The optical
density (OD) was determined at 450 nm and the stimulation
index (SI) was calculated using the following formula: SI =
mean OD of ConA-stimulated cells/mean OD of non-
stimulated cells.
Antibody assay by enzyme-linked immunosorbent assay
Blood samples were collected from the birds in each
experimental group both before the challenge and at 10 days
after the challenge. The serum antibody titers of the
experimental groups were determined using an infectious
bursal disease antibody test kit (IDEXX, USA) as described
elsewhere [17]. Titers >396 were considered positive.
Statistical analysis
All the analyses were performed using the statistical package
SAS 8.01 (SAS Institute, USA). The non-parametric Kruskal-
Wallis rank test with a pairwise multiple comparison, which
used the Dunn method for post-hoc analysis, was used to
evaluate the differences in the B/B ratios between the groups
[49]. One-way ANOVA was used to assess the individual
differences in the serum antibody titers and lymphocyte
proliferation assays. The Levene's test for homogeneity of
the data was used to determine the equality of the variances
among the groups [12]. A P-value <0.05 was considered
significant.
Results
In vitro transcription and translation
The protein expressed by pcDNA-ChIFN-γ was detected
using an in vitro transcription/ translation and detection
system (Fig. 1), and a band with a molecular weight of 17-
18 kDa was observed. According to the observations
reported by Song et al. [35], the molecular weight of the
recombinant ChIFN-γ expressed in E. coli was 17-18 kDa,
which corresponds to the nonglycosylated ChIFN-γ form.
Evaluation of adjuvant in chickens
The protective efficacy against IBDV in the chickens
immunized with the DNA vaccine mixed with selected
adjuvants, DDA, CpG-ODN and ChIFN-γ was examined by
challenging the chickens with the IBDV SH/92 strain two
weeks after the second immunization and observing them
clinically for 10 days. The efficacy of the adjuvants in these
chickens was evaluated by the mortality, B/B ratios, serum
antibody titers, and peripheral blood and splenic lymphocyte
proliferation assays (Table 1, Fig. 2 & 3).
The clinical signs (anorexia, depression, and ruffled
feathers) began to appear on three days after the challenge,
and the mortality peaked over a period of 4-5 days after the
challenge. The groups that received the DNA vaccine plus
DDA or CpG-ODN had significantly lower survival rates
than the group given the DNA vaccine alone (p < 0.05).
However, the survival rates of the groups given the DNA
vaccine alone and DNA vaccine plus ChIFN-γ were similar
Fig. 1. Colorimetric detection of SDS-PAGE analysis of  a
coupled in vitro transcription/translation reaction (Promega).
Lane 1 = SDS-PAGE molecular weight standard, broad range
(Invitrogen); Lane 2 = pcDNA-ChIFN-γ. The position of the
interferon gamma protein is on the right side. The sizes of the
marker proteins are indicated on the left.364 Ha Jung Roh et al.
(p > 0.05). In particular, the DNA vaccine plus DDA group
showed a similar mortality to the challenge control group.
Bursal atrophy in the chickens receiving the DNA vaccine
plus CpG-ODN or ChIFN-γ was severe compared with that
observed with the DNA vaccine alone and with the normal
control group (Fig. 2). The bursae of the challenge control
and the DNA vaccine plus DDA groups were not evaluated
because all the chickens in this group died within the post-
challenge period. The B/B ratio for the DNA vaccine plus
CpG-ODN group was not significantly lower than that
observed with the DNA vaccine alone (p > 0.05) (Table 1).
The B/B ratio for the DNA vaccine plus ChIFN-ã was lower
than for the DNA vaccine alone or normal control but the
difference was not significant (p > 0.05).
None of the chickens in all groups had any detectable
antibodies to the IBDV before the challenge. However, all
the surviving chickens of each group except for the normal
control group showed detectable antibodies to the IBDV at
day 10 after the challenge (Table 1). Similar ELISA antibody
titers were detected in all groups except for the normal
control group (p > 0.05).
The kinetic changes in ConA-induced peripheral blood
and splenic lymphocyte proliferation in the chickens in each
group were measured using the WST-8 assay before and
after the challenge with the IBDV SH/92 strain (Fig. 3). The
SI of the peripheral blood in all groups was similar
immediately before the challenge except for the normal
control group (p > 0.05). The SI at day 10 post-challenge in
the DNA vaccine plus CpG-ODN or ChIFN-γ groups was
almost identical to those of the group receiving the DNA
vaccine alone. The SI for the splenic lymphocytes on day 10
after the challenge were higher in the DNA vaccine plus
CpG-ODN and ChIFN-ã groups than in the DNA vaccine
control group but the difference was not significant (p >
0.05).
Discussion
Various compounds have been examined and recommended
as adjuvants for stimulating the immune response. However,
the commercially available adjuvants are still mostly limited
Table 1. Protection efficacy of the adjuvants, as determined by mortality and bursal weight/ body weight (B/B) ratio, at day 10 after t he
challenge with the virulent IBDV SH/92 strain, and by the antibody titer to the IBDV, as determined by enzyme- linked immunosor bent
assay (ELISA), in serum collected from the chickens before the challenge and at day 10 after the challenge
Group
A Mortality




D (mean ± SD)
Prechallenge Post-challenge
Normal control 0/9 (0) 5.09 ±1.75a
F<396 (0/9)
F <396 (0/9)
Challenge control 9/9 (100)a - 
E <396 (0/9) -
DNA vaccine alone 5/9 (56)c 4.56 ± 2.13ab <396 (0/9) 10626.75 ± 6150.98a (4/4)
DNA vaccine plus DDA 9/9 (100)a - <396 (0/9) -
DNA vaccine plus CpG 7/9 (78)b 1.51 ± 0.44b <396 (0/9) 17436.50 ± 1470.08a (2/2)
DNA vaccine plus IFN-γ 6/9 (67)bc 2.04 ± 0.21ab <396 (0/9) 14118.33 ± 1192.05a (3/3)
ANormal control: without vaccine and challenge; Challenge control: without vaccine but with the challenge; DNA vaccine alone: wi th pcDNA-VP243
DNA vaccine and with the challenge; DNA vaccine plus DDA: with pcDNA-VP243 mixed with DDA and with the challenge; DNA vaccine p lus CpG-
ODN: with pcDNA-VP243 mixed with CpG-ODN and with the challenge; DNA vaccine plus chIFN- γ: with pcDNA-VP243 and plasmid encoding
chIFN-γ and with the challenge. At week 2 after the second vaccination, all groups except the normal control group were orally challen ged with 1×10
4.8
ELD50 of the virulent IBDV SH/92 strain.
BMortality was recorded during the 10 day period and is presented as the number of dead chickens/total number of chickens in eac h group. The values
followed by the different lowercase superscripts are significantly different ( p <0 . 0 5 ) .
CB/B (Bursal/body weight) ratio was calculated by (bursa weight)/(body weight) ×1000 and presented as the mean ± SD from each grou p. The values
followed by different lowercase superscripts are significantly different ( p <0 . 0 5 ) .
DELISA titers were determined using an ELISA kit (IDEXX, USA) according to the procedures recommended by the manufacturer. Titer s greater than
396 are considered to be positive. Titer-Relates S/P at a 1:500 dilution to an endpoint titer: log 10 titer = 1.09 (log10 S/P) + 3.36 (FlockCheck program).
Each value represents the mean ELISA optical density obtained from the chickens ± SD. The values followed by the same lowercase s uperscripts are
not significantly different (p >0 . 0 5 ) .
ENone of the birds in this group survived to 10 days after the challenge.
FNumber of positive serum samples/number of tested serum samples.
Fig. 2. The size and morphology of the representative bursa of
Fabricius recovered from the chickens with or without the DNA
vaccine at day 10 post-challenge with the virulent IBDV SH/92
strain. At week 2 after the second vaccination, all the groups
except for the normal control group were orally challenged wit h
1×1 0
4.8 ELD50 of the virulent IBDV SH/92 strain.Effects of adjuvants on IBDV DNA vaccines 365
to the conventional adjuvants that contain oil emulsions and
insoluble salts of aluminum [13]. Although mineral oil
emulsions are used in a wide range of food animals, their
undesirable side effects, such as deterioration in the meat
quality at the injection sites and the risk of mineral oil
residues in the meat from these animals, highlights the need
for new adjuvants [13]. This study evaluated DDA, CpG-
ODN and ChIFN-γ, which have been reported to be
immunomodulators against various infectious diseases in
many animal models [7,14,16,22,42], as adjuvants for
pcDNA-VP243 vaccine against IBDV [17].
The pre-challenge serum antibody titers of the chickens,
whether vaccinated or not, were all negative as tested by
ELISA, but all the post-challenge serum samples revealed
high antibody titers except for the normal control group. The
commercial IBDV antibody test kit used in these experiments
was specifically designed to evaluate the immune status of
the chickens for the IBDV, and only those serum samples
with antibody titers >369 were considered positive. Although
it was reported that protection against IBDV correlates with
the levels of neutralizing antibodies in chickens [26], the
antibody titers for the DNA vaccine alone and for our
adjuvant groups were not in proportion to their mortality or
B/B ratios. However, there were no significant differences
between the groups receiving the DNA vaccine alone and
those receiving the DNA vaccine plus CpG-ODN or
ChIFN-γ. This is despite the fact that the adjuvant groups
had higher mortality rates than the group given the DNA
vaccine alone. It appears that other protective mechanisms
might have been induced in the chickens from the vaccine-
only group. The chickens were partially or fully protected
against the IBDV challenge, even though the VP2-VP4-
VP3-expressing plasmid, which was constructed with the
classical IBDV strain STC, induced only low or undetectable
levels of antibodies in the chickens before the challenge [3].
In this study, the high post-challenge serum antibody titers
appeared to have been induced by the challenge virus.
The lymphocyte proliferation assay is widely used to
evaluate the cell-mediated immune responses in chickens in
the normal and disease states [27,29]. The DNA vaccine
alone and DNA vaccine plus CpG-ODN or ChIFN- γ produced
in higher levels of peripheral lymphocyte proliferation in
response to ConA at 10 days post-challenge than the pre-
challenge. However, the differences between these groups
were not statistically significant. In addition, the splenic
lymphocyte proliferation assay at day 10 post-challenge
showed a similar of mitogenic response between the 3
groups. In a previous study with the DNA vaccine [17], the
level of peripheral blood lymphocyte proliferation in the
challenge control group decreased after the challenge.
DDA has been identified as an effective enhancer of the
immune response to bacteria [15] and viruses [18,19] in
mammalian models. In chickens, DDA enhanced the antibody
response after a secondary boost with the Newcastle disease
virus vaccine [33] and augmented the humoral and T-cell
immunity to coccidial antigens [23]. DDA improved the
pseudorabies virus-specific humoral immune and cell-
mediated responses after DNA vaccination against the
psedorabies virus [41]. However, DDA had an adverse
effect on the efficacy of the pcDNA-vp243 vaccine based on
the mortality and B/B ratio when co-administered with the
DNA vaccine. The amount or preparation method of DDA
might have to be modified in future studies because several
researchers have used various DDA formulations in their
experiments.
The efficacy of CpG-ODNs as immunomodulators has
been reported in many studies [20,24,36,37,47,48]. According
to these studies, CpG-ODNs activate and induce the
maturation of several cells such as B cells, macrophages,
NK cells and dendritic cells which play important roles in
the immune system. However, the CpG-ODNs used in this
study worsened the DNA vaccine effect. Although the co-
administration of DNA vaccine with CpG-ODNs (ODN2007)
in chickens surviving after challenge induced an almost
identical antibody titer and a similar stimulation index score
in the lymphocyte proliferation assay compared to those
obtained with DNA vaccine alone, co-administration also
increased the mortality rate and induced bursal atrophy. This
Fig. 3. The mitogenic responses of peripheral blood (A) and
splenic (B) lymphocytes prepared from randomly selecte d
chickens with or without DNA vaccines after the challenge wit h
the virulent IBDV SH/92 strain. Within the same day, the values
followed by the different lowercase superscripts are significantly
different (p < 0.05). All the birds in the challenge control and
DNA vaccine plus DDA groups died within 10 days after the
challenge.366 Ha Jung Roh et al.
suggests that the CpG-ODN was not an effective immuno-
modulator for the pcDNA-VP243 DNA vaccine. Another
CpG-ODN (ODN2135) previously showed a high stimulation
index in a proliferation assay of PBMC in the peripheral
blood from chickens [32] in another experiment. However,
there was no significant difference between the pcDNA-
VP243 alone and pcDNA-VP243 plus ODN2135 (data not
shown). Conflicting results obtained with the co-administration
of DNA vaccines and CpG-ODNs were reported [43,44].
The co-administration of CpG oligodeoxynucleotide with
the DNA vaccines against IBDV carrying VP2 genes
enhanced the protective immune response of the DNA
vaccine in chickens [43]. However, the DNA vaccine, the
CpG oligodeoxynucleotide, and the formulations used were
different from these experiment. An ODN dose-dependent
reduction in gene expression from a plasmid was reported in
mice [44]. Different formulations (different times or sites) of
the CpG-ODN and DNA vaccine also did not augment the
antibody responses, possibly due to competition between the
CpG-ODN and DNA vaccine for entry into the cells in
addition to the lower nuclear resistance and poor stability of
CpG-ODN in vivo. Several types of CpG-ODNs have been
studied  in vitro and in vivo [32]. The other CpG-ODNs
might augment immune response to the pcDNA-VP243
DNA vaccine.
The effects of IFN-γ on the immune response appear to be
dependent upon the animal species and age, the types of
combined antigen, the nature and dose of IFN-γ, and the
particular promoter/enhancer of the plasmid expressing the
foreign gene. The co-administration of ChIFN-γ expressed
using a baculovirus system with the inactivated Salmonella
enteritidis antigen enhanced the level of protection against
Salmonella enteritidis challenge without increasing the
antibody production [39]. The co-administration of the
recombinant ChIFN-γ with sheep red blood cell antigens
resulted in stronger antibody responses and allowed a lower
dose of the antigen to be used more effectively than in the
chickens that received the antigen alone [25]. Harms et al.
[10] reported a down-regulatory effect of IFN-γ on both the
SV40 and CMV promoter/enhancer-driven transgenes in
most cell lines tested, and an up-regulatory effect of IFN-γ
on the MHC I promoter/enhancer-driven transgene in all the
cell lines tested. In particular, the addition of IFN-γ in
myoblasts drastically reduced the SV40 and CMV promoter-
driven expression in myoblasts. 
The effect of IFN-γ depended upon the promoter driving
expression of the viral antigen. The immune responses to the
antigen-expressing vectors carrying a viral promoter such as
the SV40 were lower in presence of IFN- γ. However, IFN-γ
had no effect on a vector expressing the antigen under the
control of the MHC class II promoter [46]. In this experiment,
the ChIFN-γ-expressing plasmid under the control of the
CMV promoter given at separate site did not increase the
level of protection against the vvIBDV by the IBDV DNA
vaccine. In another experiment, the ChIFN-γ-expressing
plasmid co-injected with the IBDV DNA vaccine at the
same site had an adverse effect on the level of protection
against the vvIBDV in chickens (data not shown). The
inhibitory effect of IFN-γ was stronger with the co-injected
DNA vaccine than with the separately injected DNA
vaccine, which suggests that the effect of IFN-γ might occur
locally. These results agree with the results of most other
researchers using the CMV or SV40 promoter/enhancer-
driven transgenes, although the antigens expressed in the
plasmids were different.
These studies showed that CpG-ODN and ChIFN-γ had
no significant adjuvant effect and DDA had a negative effect
on the DNA vaccine of pcDNA-VP243. Further studies will
be needed to identify the optimal adjuvants for the DNA
vaccine against the IBDV. 
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